Browse the evidence

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

Obesity as a treatment indication was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 2.46).

Patients with obesity may experience better weight loss outcomes compared to those with type 2 diabetes.

Persistent medication coverage was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 3.36).

Ensuring patients maintain their medication regimen may significantly improve weight loss outcomes.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Using tirzepatide resulted in a weight loss of 17.8% compared with 12.4% for semaglutide.

Tirzepatide may be more effective for weight loss in patients with type 2 diabetes.

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.

Practitioners can consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

An active perioperative GLP-1 RA prescription in patients with diabetes was associated with a significantly reduced risk of 30-day readmission (RR: 0.883; P = 0.028).

Practitioners may consider GLP-1 RA prescriptions to reduce readmission rates in diabetic surgical patients.

The percentage of weight loss as fat-free mass (%FFML) using GLP-1RA-based agents was between 20% and 40%.

Practitioners can expect that GLP-1RA treatments may lead to significant fat-free mass loss.

AOMs have established efficacy and effectiveness for weight loss even beyond 52 weeks.

Practitioners can consider AOMs as effective long-term options for weight management.

Medication options are available to treat obesity, which can help reduce appetite and/or reduce caloric intake.

Practitioners can consider pharmacological treatments to assist patients in managing obesity.

GLP-1 receptor agonists have been successfully used in the treatment of obesity and type 2 diabetes.

GLP-1 receptor agonists can be considered as a treatment option for patients with obesity and T2DM.

Tirzepatide has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.

Tirzepatide may be a more effective option for managing HbA1c and body weight in patients compared to existing therapies.

Semaglutide therapy resulted in a 62.9% resolution of MASH without worsening of fibrosis compared to 34.3% in placebo (p <0.001).

Clinicians can consider semaglutide as an effective treatment option for MASH with moderate-to-advanced fibrosis.

Obesity increases the risk for Type 2 diabetes, hypertension, and cardiovascular disease.

Healthcare providers should prioritize weight management in patients with cardiovascular disease.

Recent guidelines prioritize pharmacologic interventions for weight management in Type 2 diabetes.

Healthcare providers should consider pharmacologic options for weight management in diabetic patients.

The oral formulation of semaglutide reduced AF incidence by 52%.

The oral formulation of semaglutide may be particularly effective in reducing AF risk.

Semaglutide use is effective in patients with IBD and obesity, resulting in a mean weight loss of over 5%.

Clinicians can consider semaglutide as a viable weight loss option for patients with IBD and obesity.

Semaglutide is associated with weight loss in adults.

Practitioners can consider semaglutide as a treatment option for weight loss in adults with type 2 diabetes or obesity.

Semaglutide improves control of diabetes in adults.

Practitioners can utilize semaglutide to enhance diabetes management in adults.

GLP-1 receptor agonists (GLP-1 RA) are a safe and effective treatment for weight regain and insufficient weight loss after metabolic bariatric surgery.

Practitioners can consider GLP-1 RA as a viable option for patients struggling with weight management post-surgery.

Weekly semaglutide leads to significantly greater weight loss compared to daily liraglutide.

Clinicians may prefer semaglutide over liraglutide for enhanced weight loss outcomes.